November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Mike Thompson: Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease
Oct 27, 2024, 17:41

Mike Thompson: Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease

Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared on X:

“S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease to direct Therapy Duration (DRAMMATIC) – Amrita Krishnan, Hoering, Phari, Sexton, Robert Z. Orlowski.

ASH20 Abstract 1515

1515 Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Authors: Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton, Robert Z. Orlowski

Mike Thompson: Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease